Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.
https://www.soleburytrout.com/lifesciences
TroutTalks Ep 3: Dr. Louis Weiner - "Antibody Therapy of Cancer: The Revolution Continues”
Dr. Louis Weiner, Director of the Lombardi Cancer Center, Board member of the Antibody Society, and co-founder of Jounce Therapeutics is an internationally recognized medical oncologist specializing in the treatment in gastrointestinal cancers. Additionally, Dr. Weiner is an accomplished researcher developing novel immunotherapy treatments for cancer, widely known for his work in antibody-based therapeutics, including the development of bi-specific antibodies.